KR102483410B1 - 암 줄기세포와 연관된 암의 진단 및 치료 - Google Patents

암 줄기세포와 연관된 암의 진단 및 치료 Download PDF

Info

Publication number
KR102483410B1
KR102483410B1 KR1020217031149A KR20217031149A KR102483410B1 KR 102483410 B1 KR102483410 B1 KR 102483410B1 KR 1020217031149 A KR1020217031149 A KR 1020217031149A KR 20217031149 A KR20217031149 A KR 20217031149A KR 102483410 B1 KR102483410 B1 KR 102483410B1
Authority
KR
South Korea
Prior art keywords
cancer
delete delete
cells
cldn6
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217031149A
Other languages
English (en)
Korean (ko)
Other versions
KR20210120142A (ko
Inventor
우구르 사힌
외즐렘 튀레시
코르덴 발터
마이케 바그너
마리아 크로이츠베르크
사비네 해커
슈테판 야콥스
Original Assignee
비온테크 에스이
가니메드 파마슈티칼스 게엠베하
트론-트란슬라셔날레 온콜로기 안 데어 유니버시태츠메디진 데어 요하네스 구텐베르크-유니버시태트 마인츠 게마인뉘치게 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비온테크 에스이, 가니메드 파마슈티칼스 게엠베하, 트론-트란슬라셔날레 온콜로기 안 데어 유니버시태츠메디진 데어 요하네스 구텐베르크-유니버시태트 마인츠 게마인뉘치게 게엠베하 filed Critical 비온테크 에스이
Priority to KR1020227045732A priority Critical patent/KR102663127B1/ko
Publication of KR20210120142A publication Critical patent/KR20210120142A/ko
Application granted granted Critical
Publication of KR102483410B1 publication Critical patent/KR102483410B1/ko
Assigned to 아스테라스 세이야쿠 가부시키가이샤 reassignment 아스테라스 세이야쿠 가부시키가이샤 권리지분의 전부이전등록 Assignors: 가니메드 파마슈티칼스 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G01N33/57484—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020217031149A 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료 Active KR102483410B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227045732A KR102663127B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/002272 2013-07-31
PCT/EP2013/002272 WO2015014376A1 (en) 2013-07-31 2013-07-31 Diagnosis and therapy of cancer involving cancer stem cells
KR1020167005323A KR102308813B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료
PCT/EP2014/066330 WO2015014870A1 (en) 2013-07-31 2014-07-30 Diagnosis and therapy of cancer involving cancer stem cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167005323A Division KR102308813B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045732A Division KR102663127B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료

Publications (2)

Publication Number Publication Date
KR20210120142A KR20210120142A (ko) 2021-10-06
KR102483410B1 true KR102483410B1 (ko) 2022-12-30

Family

ID=48914215

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217031149A Active KR102483410B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료
KR1020227045732A Active KR102663127B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료
KR1020247014359A Active KR102867808B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료
KR1020167005323A Active KR102308813B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227045732A Active KR102663127B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료
KR1020247014359A Active KR102867808B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료
KR1020167005323A Active KR102308813B1 (ko) 2013-07-31 2014-07-30 암 줄기세포와 연관된 암의 진단 및 치료

Country Status (19)

Country Link
US (3) US10604568B2 (https=)
JP (5) JP2016533738A (https=)
KR (4) KR102483410B1 (https=)
CN (3) CN113406327B (https=)
AR (1) AR097178A1 (https=)
AU (3) AU2014298505B2 (https=)
BR (1) BR112016002000A2 (https=)
CA (1) CA2919570A1 (https=)
DK (1) DK3027208T3 (https=)
ES (2) ES2807181T3 (https=)
HU (1) HUE050622T2 (https=)
IL (4) IL308523B2 (https=)
MX (2) MX385872B (https=)
NZ (1) NZ716473A (https=)
PT (1) PT3027208T (https=)
RU (2) RU2749867C2 (https=)
SG (2) SG11201600722PA (https=)
UA (1) UA123428C2 (https=)
WO (2) WO2015014376A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300421T1 (it) 2009-02-20 2024-01-10 Astellas Pharma Inc Metodi e composizioni per la diagnosi e il trattamento del cancro
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2989943T3 (es) 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
JP6408134B2 (ja) * 2015-03-31 2018-10-17 三菱日立パワーシステムズ株式会社 燃焼バーナ及びボイラ
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
US20180371550A1 (en) * 2015-07-08 2018-12-27 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
TWI767915B (zh) 2016-06-27 2022-06-21 加州大學董事會 Ror-1與btk拮抗劑的組合
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
US10947316B2 (en) * 2017-06-15 2021-03-16 Development Center For Biotechnology Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof
WO2019048040A1 (en) * 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
EP3681993B1 (en) 2017-09-13 2026-04-01 BioNTech SE Rna replicon for reprogramming somatic cells
NO20210351A1 (en) * 2017-09-18 2021-03-18 Univ California Claudin6 antibodies and methods of treating cancer
NZ762505A (en) 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3838291A4 (en) * 2018-08-13 2022-05-11 Cancerstem Tech Inc. CANCER STEM CELL MARKERS AND ANTI-CANCER STEM CELL PHARMACEUTICALS
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
MX2022000111A (es) 2019-07-10 2022-02-10 Chugai Pharmaceutical Co Ltd Moleculas de union a claudina-6 y usos de las mismas.
CN111087465B (zh) * 2019-12-24 2020-12-08 广州医科大学 一种针对密蛋白6的抗体偶联药物及应用
CN113832226B (zh) * 2020-06-24 2023-06-30 广州医科大学附属第五医院 研究gnl3与肝癌发展的相关性的方法及gnl3作为肝肿瘤干细胞、肝癌标志物的用途
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
WO2024165057A1 (en) * 2023-02-07 2024-08-15 LaNova Medicines Limited Antibodies and antibody-drug conjugates targeting claudin 6
IL324834A (en) 2023-05-25 2026-01-01 Univ California Dosage of claudin-6 conjugates for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057788A1 (en) 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2012003956A1 (en) 2010-07-06 2012-01-12 Ganymed Pharmaceuticals Ag Cancer therapy using cldn6 target-directed antibodies in vivo

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO2000073348A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
AU773028B2 (en) 1998-11-03 2004-05-13 Adherex Technologies Inc. Compounds and methods for modulating claudin-mediated functions
AU3124000A (en) 1998-12-17 2000-07-03 Human Genome Sciences, Inc. 47 human secreted proteins
JP2002536995A (ja) 1999-02-22 2002-11-05 インサイト・ファーマスーティカルズ・インコーポレイテッド 結腸の疾患に関連する遺伝子
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
CA2402563A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001236470A1 (en) 2000-01-14 2001-07-24 Corixa Corporation Ovarian tumor-associated sequences
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001273150A1 (en) 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030100713A1 (en) 2000-07-25 2003-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PT2000545E (pt) 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US20070207142A1 (en) * 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
AU2003303144A1 (en) 2002-10-18 2004-07-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
US20050031615A1 (en) 2003-05-30 2005-02-10 Anderson G. Mark Method of inhibiting tumor growth with anti-tissue factor antibodies
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
DE102005025041A1 (de) 2005-05-30 2006-12-07 Bell Flavors & Fragrances Duft Und Aroma Gmbh Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2368908A3 (en) * 2006-11-10 2011-10-12 CovX Technologies Ireland Limited Anti- angiogenic compounds
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
WO2009120905A2 (en) * 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
AU2009234259A1 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of Gleditsia sinensis Lam
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
DE102009026966A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Betrieb eines Bremskraftverstärkers als Pedalsimulator
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
SMT202300421T1 (it) 2009-02-20 2024-01-10 Astellas Pharma Inc Metodi e composizioni per la diagnosi e il trattamento del cancro
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
WO2011105551A1 (ja) 2010-02-26 2011-09-01 国立大学法人大阪大学 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤
JP2011213612A (ja) * 2010-03-31 2011-10-27 Kyowa Hakko Kirin Co Ltd 癌幹細胞及び／または癌前駆細胞の減少剤
ES2989943T3 (es) 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
KR101242726B1 (ko) 2012-01-26 2013-03-13 한국과학기술원 종양줄기세포 특성 암의 진단 및 치료제
EP2875046B2 (en) 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
JP6499079B2 (ja) * 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
BR112015022855A2 (pt) * 2013-03-14 2017-11-07 Shire Human Genetic Therapies composições e método para produção de um anticorpo in vitro
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057788A1 (en) 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2012003956A1 (en) 2010-07-06 2012-01-12 Ganymed Pharmaceuticals Ag Cancer therapy using cldn6 target-directed antibodies in vivo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ben-David Uri et al, Nature Communications (2013.06.18.), vol 4, pp 1992, XP008168176, ISSN:2041-1723.
Tetsuo Ushiku et al, Histopathology (2012.07.17.), vol 61, no 6, pp 1043-1056.

Also Published As

Publication number Publication date
JP2019110907A (ja) 2019-07-11
NZ716473A (en) 2022-02-25
IL308523B1 (en) 2025-01-01
US10604568B2 (en) 2020-03-31
JP7136822B2 (ja) 2022-09-13
MX385872B (es) 2025-03-18
KR20160034417A (ko) 2016-03-29
ES3041948T3 (en) 2025-11-17
HUE050622T2 (hu) 2021-01-28
IL293880B1 (en) 2024-03-01
IL243408A0 (en) 2016-03-31
US20200385460A1 (en) 2020-12-10
UA123428C2 (uk) 2021-04-07
AU2020201331A1 (en) 2020-03-12
AU2022206711B2 (en) 2025-09-04
CN113406327B (zh) 2023-10-31
SG10201800834RA (en) 2018-03-28
ES2807181T3 (es) 2021-02-22
JP2016533738A (ja) 2016-11-04
JP6865778B2 (ja) 2021-04-28
US20160159901A1 (en) 2016-06-09
WO2015014870A1 (en) 2015-02-05
CA2919570A1 (en) 2015-02-05
AU2022206711A1 (en) 2022-08-11
WO2015014376A1 (en) 2015-02-05
RU2749867C2 (ru) 2021-06-17
IL293880A (en) 2022-08-01
BR112016002000A2 (pt) 2017-08-29
CN113252898A (zh) 2021-08-13
KR102867808B1 (ko) 2025-10-13
AU2020201331B2 (en) 2022-04-21
RU2016107005A (ru) 2017-09-04
KR102308813B1 (ko) 2021-10-06
SG11201600722PA (en) 2016-02-26
CN105407922B (zh) 2021-06-25
IL293880B2 (en) 2024-07-01
MX2016001186A (es) 2016-07-15
KR102663127B1 (ko) 2024-05-07
JP2025011178A (ja) 2025-01-23
JP2020101558A (ja) 2020-07-02
KR20240060738A (ko) 2024-05-08
AU2014298505B2 (en) 2019-12-19
KR20210120142A (ko) 2021-10-06
IL243408B (en) 2022-07-01
DK3027208T3 (da) 2020-07-27
PT3027208T (pt) 2020-07-20
US11795218B2 (en) 2023-10-24
JP7611196B2 (ja) 2025-01-09
IL308523B2 (en) 2025-05-01
RU2020123616A (ru) 2020-09-10
JP2023009039A (ja) 2023-01-19
KR20230007548A (ko) 2023-01-12
AR097178A1 (es) 2016-02-24
RU2016107005A3 (https=) 2018-03-30
CN113406327A (zh) 2021-09-17
CN105407922A (zh) 2016-03-16
MX2021010672A (es) 2021-12-10
US20240059772A1 (en) 2024-02-22
AU2014298505A1 (en) 2016-02-18
IL308523A (en) 2024-01-01
IL310824A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
JP7611196B2 (ja) 癌幹細胞を含む癌の診断および治療法
EP3027208B1 (en) Diagnosis and therapy of cancer involving cancer stem cells
HK40040517A (en) Diagnosis and therapy of cancer involving cancer stem cells
HK40040716A (en) Diagnosis and therapy of cancer involving cancer stem cells
HK40061772B (zh) 涉及癌症干细胞的癌症的诊断与治疗
HK1223543A1 (en) Diagnosis and therapy of cancer involving cancer stem cells
HK1223543B (en) Diagnosis and therapy of cancer involving cancer stem cells

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000